Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GT005

            Therapeutic Area: Ophthalmology Product Name: GT005

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering May 07, 2021

            Details:

            Proceeds from the financing to be used in continuing to advance Gyroscope's clinical program for its investigational gene therapy, GT005, as well as our earlier stage pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GT005

            Therapeutic Area: Ophthalmology Product Name: GT005

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Forbion’s Growth Opportunities Fund

            Deal Size: $148.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing March 26, 2021

            Details:

            Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005, the company’s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).